J&J: applies to EMA for extended indication for Rybrevant
(CercleFinance.com) - The Janssen pharmaceutical companies of Johnson & Johnson announce that they have applied to the European Medicines Agency for an extension of the indication for Rybrevant (amivantamab), to be used in combination with chemotherapy (carboplatin and pemetrexed), in the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with so-called EGFR mutations.
While patients facing such a diagnosis are generally faced with little probability of survival, Martin Vogel, EMEA Therapeutic Area Manager Oncology, believes that this application to the EMA aims to change the trajectory of care through earlier intervention with targeted treatment options for patients who are eligible.
The application is based on a Phase III clinical trial that showed a statistically and clinically significant improvement in progression-free survival in patients receiving amivantamab in combination with chemotherapy, compared with chemotherapy alone.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
While patients facing such a diagnosis are generally faced with little probability of survival, Martin Vogel, EMEA Therapeutic Area Manager Oncology, believes that this application to the EMA aims to change the trajectory of care through earlier intervention with targeted treatment options for patients who are eligible.
The application is based on a Phase III clinical trial that showed a statistically and clinically significant improvement in progression-free survival in patients receiving amivantamab in combination with chemotherapy, compared with chemotherapy alone.
Copyright (c) 2023 CercleFinance.com. All rights reserved.